Real Endpoints, a recognized leader in providing insights, support and tools to strengthen access to pharmaceutical innovation for an evolving healthcare landscape focuses entirely on delivering solutions that enhance appropriate access to innovation. To do this, we leverage insights from our close working relationships with payers and biopharma; objective, data-driven proprietary tools; and – above all – the creativity and deep experience of our people. In particular, Real Endpoints focuses on three main activities: • Helping to define, through objective clinical and economic assessment and practical evidence strategies, a product’s value for patients and payers; • Translating that value into coverage with effective pricing strategies and innovative, contracting approaches, including risk sharing and outcomes-focused arrangements;• And finally, strategies for supporting patients and providers in order to go beyond mere coverage and win actual access to new diagnostics and medicines.

Novos Growth Partners offers turn key, fully-integrated commercialization solutions for specialty pharmaceutical products.The Novos Business System is designed to address the key challenges facing pharmaceutical companies today with:-Tools: Comprehensive set of industry-leading and cutting-edge strategies, tactics, and tools that move faster than the market-People: Team of functional experts that have been at the forefront of innovation and driven some of the most notable turnarounds and launches in the last five years-Capital Efficient Approach: Value-maximizing and capital-efficient approach to resource deploymentWe have a strong track record of success across a wide range of therapeutic classesNovos Growth Partners has the flexibility to structure relationships based on the needs of our partners, but we typically partner through a service agreement, performance-based consulting agreement, out-licensing agreement, or acquisition.